Australian laws and regulations limit the amount of information we can provide to the general public via our website. Our Consumer Medicine Information (CMI) leaflets are intended for patients who have been prescribed our products. They provide information on the safe and effective use of the prescription medicine. Our Product Information (PI) sheets are intended for healthcare professionals. They provide a summary of the essential scientific information for the safe and effective use of a prescription medicine.
Pain
DILAUDID® tablets and liquid
immediate release hydromorphone hydrochloride
DILAUDID® & DILAUDID®HP INJECTIONS
hydromorphone hydrochloride
MS CONTIN® tablets
modified release morphine sulfate
MS CONTIN® suspension
modified release morphine sulfate
MS MONO® capsules
modified release morphine sulfate
Norspan® Patch
transdermal buprenorphine matrix patch
ORDINE® oral solution
immediate release morphine hydrochloride
OxyContin® tablets
modified release oxycodone hydrochloride
OxyNorm® capsules and liquid
immediate release oxycodone hydrochloride
OxyNorm® injection
immediate release oxycodone hydrochloride
SEVREDOL® tablets
immediate release morphine sulfate
TARGIN® tablets
modified release oxycodone and modified release naloxone hydrochloride dihydrate
® DILAUDID, MS CONTIN, MS MONO, NORSPAN, OXYCONTIN, OXYNORM, SEVREDOL and TARGIN are registered trade marks.
® ORDINE is a registered trade mark of Pfizer (Perth) Pty Ltd and is used under licence.
*Due to unforeseen manufacturing issues, DILAUDID® oral liquid (hydromorphone 1mg/mL) is unavailable. It is anticipated that supply will recommence in October 2017. If you are a patient, please speak with your doctor. Please call Mundipharma Medical Information (1800-188-009) for information on Mundipharma products.